Piggott L M, Hayes C, Greene J, et al.Malignant pleural disease[J]. Breathe (Sheff), 2023,19(7):230145.
[2]
Murthy V, Katzman D, Sterman D H. Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy[J]. Clin Respir J, 2019,13(5):272-279.
[3]
Verma V, Ahern C A, Berlind C G, et al. National cancer database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma[J]. J Thorac Oncol,2017,12(11):1704-1714.
[4]
Agrawal A, Chaddha U, Shojaee S, et al. Intrapleural anticancer therapy for malignant pleural diseases: facts or fiction[J].Semin Respir Crit Care Med. 2023,44(4):462-467.
[5]
Ambrogi M C, Bertoglio P, Aprile V, et al. Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: a 10-year experience[J]. J Thorac Cardiovasc Surg, 2018,155(4):1857-1866.
[6]
Baldini E H, Richards W G, Gill R R, et al.Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma[J]. J Thorac Cardiovasc Surg, 2015,149(5):1374-1381.
[7]
Migliore M, Ried M, Molins L, et al. Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma[J]. Ann Transl Med, 2021,9(11):960.
[8]
Kimura M, Tojo T, Naito H, et al. Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination[J].Interact Cardiovasc Thorac Surg, 2010,10(4):568-571.
[9]
Migliore M, Nardini M. Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion? [J]. Eur Respir Rev, 2019,28(153): 190018.
[10]
Pan X, Hou Z, Zhang T, et al. Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis [J]. J Cardiothorac Surg, 2024,19(1):278.
[11]
Karampinis I, Dionysopoulou A, Galata C, et al. Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: a systematic literature review and pooled analysis [J].Thorac Cancer,2022,13(7):883-888.
Hu Y, Zhou Z, Luo M. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: a meta-analysis [J].Medicine (Baltimore) 2022,101(52):e32207.
[14]
Du N, Li X, Li F, et al.Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancermediated malignant pleural effusion[J]. Oncol Rep,2013, 29(6):2332-2340.
[15]
Qi N, Li F, Li X, et al. Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion[J]. Medicine (Baltimore),2016,95(47):5392.
[16]
Di W, Yue C, Ziran Z, et al. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion[J]. Future Oncol,2022,18(6):669-677.
Kawachi H, Tamiya M, Taniguchi Y, et al. Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous nsclc with malignant pleural effusion: a retrospective multicenter cohort study[J]. JTO Clin Res Rep,2022,3(7):100355-100365.
[19]
Wei Q, Deng T, Wu J, et al. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study[J].BMC Cancer,2024,24(1):393.
[20]
Prado G H, Romero G S, Puerto A A, et al. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients[J].Cancer Immunol Immun, 2017,66(6):765-776.
[21]
Li X, Wu G, Chen C, et al. Intrapleural injection of anti-PD1 antibody:a novel management of malignant pleural effusion[J].Front Immunol,2021,12(13):760683.
[22]
Hu C Y, Zhang Y H, Wang T, et al. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer[J]. Clin Exp Immunol, 2016,186(1):106-114.
[23]
Han L, Jiang Q, Yao W, et al. Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients[J]. BMC Cancer, 2018,18(1):725.
[24]
Monnet I, Breau J L, Moro D, et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study[J]. Chest, 2002,121(6):1921-1927.
[25]
Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma[J].Cancer, 1994,74(9):2460-2467.
[26]
Beatty G L, Haas A R, Maus M V, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies[J].Cancer Immunol Res, 2014,2(2):112-120.
[27]
Haas A R, Tanyi J L, O'Hara M H, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers[J].Mol Ther, 2019,27(11):1919-1929.
[28]
Adusumilli P S, Zauderer M G, Riviere I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 Agent Pembrolizumab[J]. Cancer Discov, 2021,11(11):2748-2763.
[29]
Uchida A, Micksche M, Hoshino T. Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes[J].Cancer Immunol Immunother, 1984,18(1):5-12.
[30]
Ishida A, Miyazawa T, Miyazu Y, et al. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer[J].Respirology, 2006,11(1):90-97.
[31]
Yoshida K, Sugiura T, Takifuji N, et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515[J].Lung Cancer, 2007,58(3):362-368.
[32]
Sterman D H, Recio A, Carroll R G, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses[J].Clin Cancer Res, 2007,13(15):4456-4466.
[33]
Sterman D H, Recio A, Haas A R, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions[J]. Mol Ther,2010, 18(4):852-860.
[34]
Sterman D H, Alley E, Stevenson J P, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNα combined with chemotherapy[J]. Clin Cancer Res,2016,22(15):3791-3800.
[35]
Ekeke C N, Russell K L, Murthy P, et al. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease[J]. J Thorac Cardiovasc Surg, 2022,163(4):313-328.
[36]
Danson S J, Conner J, Edwards J G, et al. Oncolytic herpesvirus therapy for mesothelioma-a phase I/IIa trial of intrapleural administration of HSV1716[J].Lung Cancer,2020,150(19):145-151.
[37]
Simone C B, Cengel K A. Photodynamic therapy for lung cancer and malignant pleural mesothelioma[J].Semin Oncol, 2014,41(6):820-830.
[38]
Pass H I, Temeck B K, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma[J]. Ann Surg Oncol,1997,4(8):628-633.
[39]
Liu Y, Wang L, Song Q, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion[J]. Nat Nanotechnol.2022,17(2):206-216.
[40]
Fan Y, Chen A, Zhu J, et al. Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity[J]. Cancer Lett, 2024,588(9):216777.
2025, Vol. 36 
